• Target：
• TIG1

• Gene Name：
• RARRES1 TIG1

• Protein Name：
• TIG1

• Human Gene Id：
• 5918

• Human Swiss Prot No：
• P49788

• Immunogen：
• Synthesized peptide derived from human TIG1

• Specificity：
• This antibody detects endogenous levels of human TIG1

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• IHC 1:50-200, WB 1:500-2000. IF 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• Retinoic acid receptor responder protein 1 (RAR-responsive protein TIG1;Tazarotene-induced gene 1 protein)

• Observed Band(KD)：
• 51kD

• Background：
• This gene was identified as a retinoid acid (RA) receptor-responsive gene. It encodes a type 1 membrane protein. The expression of this gene is upregulated by tazarotene as well as by retinoic acid receptors. The expression of this gene is found to be downregulated in prostate cancer, which is caused by the methylation of its promoter and CpG island. Alternatively spliced transcript variant encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008],

• Function：
• induction:By tazarotene and by all the retinoic acid receptors tested.,similarity:Belongs to the protease inhibitor I47 (latexin) family.,

• Subcellular Location：
• Membrane ; Single-pass type III membrane protein .

• Expression：
• Skin,

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs